CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.
|Project Number||pCODR 10051|
|Generic Name||Aldesleukin (IL-2)|
|Strength||22 million IU/vial|
|Tumour Type||Skin and Melanoma|
|Funding Request||Administered intra-lesionally, for the treatment of in-transit metastasis from melanoma in patients who have failed or are not candidates for surgery or other treatments|
|Review Status||Notification to Implement Issued|
|Pre Noc Submission||Yes|
|Manufacturer||Novartis Pharmaceuticals Canada Inc.|
|Sponsor||Cancer Care Ontario Melanoma Disease Site Group|
|Submission Date||January 30, 2015|
|Submission Deemed Complete||February 6, 2015|
|Submission Type||New Indication|
|Prioritization Requested||Not Requested|
|Stakeholder Input Deadline ‡||February 23, 2015|
|Check-point meeting||March 26, 2015|
|pERC Meeting||May 21, 2015|
|Initial Recommendation Issued||June 4, 2015|
|Feedback Deadline ‡||June 18, 2015|
|Final Recommendation Issued||June 22, 2015|
|Notification to Implement Issued||July 8, 2015|
‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.